PapersPMID:17636753
Arginine supplementation for prevention of necrotising enterocolitis in preterm infants.
L-arginineWhat moved
1 findingHow to read these marks →- Decreases necrotising enterocolitis incidence
very limited
“There was a statistically significant reduction in the risk of developing NEC (any stage) in the arginine group compared with the placebo group [RR 0.24 (95% CI 0.10, 0.61), RD -0.21 (95% CI -0.32, -0.09)].”
- Study
- meta-analysis
- Effect
- 0.24 risk ratio, 95% CI 0.1 to 0.61
- Population
- preterm neonates given enteral or parenteral arginine supplementation vs placebo or no treatment, pooled from the single eligible trial identified by this review
Study record
- Design
- meta-analysis / systematic review, not pooled
- Species
- human
- Population
- preterm neonates given enteral or parenteral arginine supplementation for at least 7 days vs placebo or no treatment
- Participants
- not reported
- Comparator
- not stated in the paper / placebo
- Duration
- not reported
- Endpoints measured
- 3